Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gerald Proteau is active.

Publication


Featured researches published by Gerald Proteau.


Clinical Chemistry and Laboratory Medicine | 2014

Peripheral blood lymphocytes from patients with bipolar disorder demonstrate apoptosis and differential regulation of advanced glycation end products and S100B

Paraskevi Moutsatsou; James N. Tsoporis; Vasileios Salpeas; Ekaterini Bei; Basel Alevizos; Chrysoula Anagnostara; Shehla Izhar; Gerald Proteau; Emmanouil Rizos; Erifili Hatziagelaki; Ioannis K. Toumpoulis; Ioannis Rizos; Thomas G. Parker

Abstract Background: This study addresses the expression of the glycosylated proteins known as advanced glycation end products (AGEs), the calcium binding protein S100B and the apoptotic parameters cytochome c and caspase-3 activity in peripheral lymphocyte cytosolic extracts from a sample of bipolar disorder (BD) patients and healthy (control) subjects. Methods: Cross-sectional study of 35 patients with a clinical diagnosis of bipolar disease (10 euthymic, 12 depressed, 13 manic) and 10 healthy control subjects. Lymphocytes were used as a surrogate model in BD diagnosis and treatment. AGEs and S100B in lymphocyte cell extracts were measured by commercially available enzyme-linked immunosorbent assay. Results: AGEs were lower in all BD patients compared to healthy subjects. Depressed patients had approximately two-fold higher S100B levels compared to healthy subjects. Manic and depressed BD patients had increased superoxide dismutase mRNA levels. Apoptosis as measured by BAX/Bcl2 ratio, cytochrome c release, caspase-3 activity was increased in manic and depressed patients compared to healthy subjects. In the depressed patients, S100B levels correlated with cytochrome c release. Conclusions: In conclusion, our study shows decreased AGEs and increased S100B levels and caspase down-stream apoptosis in peripheral lymphocytes of BD patients that may underlie disease etiopathogenesis.


Life Sciences | 2013

S100B: Role in cardiac remodeling and function following myocardial infarction in diabetes

Forough Mohammadzadeh; Jean-Francois Desjardins; James N. Tsoporis; Gerald Proteau; Howard Leong-Poi; Thomas G. Parker

AIM S100B plays a role in cardiac remodeling following myocardial infarction (MI) and in diabetic vascular complications but not examined in diabetic myocardium. We thus examined the effects of targeted deletion of S100B gene on post-MI hearts. MAIN METHODS Coronary artery ligation or sham was performed 15 weeks after streptozotocin (STZ) or vehicle injection in wild-type (WT) and S100B knock-out (BKO) mice. Left ventricular (LV) structural and functional remodeling was studied 35 days after induction of MI. KEY FINDINGS In diabetes, post-MI remodeling exhibited an attenuated increase in LV mass, dilation, and myocyte hypertrophy in association with increased apoptosis and fibrosis and reduced matrix metalloproteinase-2 (MMP-2) activity. Despite reduced LV dilation, impairment of cardiac function was similar to non-diabetic controls. Both diabetes and MI alone induced myocardial S100B and its canonical receptor for advanced glycation end product (RAGE) expression. By contrast, in post-MI diabetic myocardium, S100B expression was attenuated. Diabetic BKO, following MI demonstrated increased ventricular dilation compared to WT, in association with greater impairment of cardiac function, GLUT4 expression and systemic AGE levels. SIGNIFICANCE These data suggest that S100B expression may serve to modulate cardiac metabolism and adverse consequences of AGE in diabetic post-MI remodeling and function.


Canadian Journal of Cardiology | 2010

Increased myocardial expression of angiopoietin-2 in patients undergoing urgent surgical revascularization for acute coronary syndromes

Neil Fam; Sara Arab; Filio Billia; R. N. N. Han; Gerald Proteau; David Latter; Lee Errett; Daniel Bonneau; R. Dunne; Peter Liu; Duncan J. Stewart

BACKGROUND Myocardial ischemia triggers the expression of multiple angiogenic factors including vascular endothelial growth factor and its receptors. However, vascular endothelial growth factor does not act in isolation. OBJECTIVE To identify other genes important in the angiogenic response to clinically relevant myocardial ischemia. METHODS AND RESULTS Paired intraoperative biopsies of ischemic and nonischemic myocardium were obtained from 12 patients with acute coronary syndromes (ACS) undergoing urgent coronary artery bypass graft surgery. Real-time polymerase chain reaction demonstrated significant upregulation of angiopoietin-2 (Ang-2) in ischemic myocardium, to a greater extent than other classical angiogenic factors. Microarray gene profiling identified Ang-2 to be among the top 10 differentially upregulated genes, in addition to genes involved in inflammation, cell signalling, remodelling and apoptosis. CONCLUSIONS The present document is the first report of microarray analysis of patients with ACS, and supports an important role for Ang-2 in the angiogenic response to severe ischemia in the human heart. Common gene expression patterns in ACS may provide opportunities for targeted pharmacological and cellular intervention.


Cardiovascular Research | 2004

Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat

Reena Sandhu; Krystyna Teichert-Kuliszewska; Sukriti Nag; Gerald Proteau; Malcolm Robb; Andrew Campbell; Michael A. Kuliszewski; Michael Kutryk; Duncan J. Stewart


Journal of Molecular and Cellular Cardiology | 2012

S100B-RAGE dependent VEGF secretion by cardiac myocytes induces myofibroblast proliferation

James N. Tsoporis; Shehla Izhar; Gerald Proteau; Graham Slaughter; Thomas G. Parker


Canadian Journal of Cardiology | 2012

Abstract session by dateCCS poster heart failure Monday posters I366 Abrogation of S100B Expression in S100A1 Deficient Mice Improves Survival Post Myocardial Infarction

J. Tsoporis; Jean-Francois Desjardins; S. Izhar; F. Mohammadzadeh; Gerald Proteau; J. Baudier; Thomas G. Parker


Canadian Journal of Cardiology | 2012

374 S100B Binding to Toll-Like Receptor 4 Induces the Proinflammatory Cytokines Tumor Necrosis Factor Alpha and Interleukin 6 Post-Myocardial Infarction

J. Tsoporis; Jean-Francois Desjardins; Gerald Proteau; S. Izhar; Thomas G. Parker


Canadian Journal of Cardiology | 2012

333 Plasma Levels of the Receptor for Advanced Glycation End Products and Its Ligands Predict Left Ventricular Apoptotic Events in Patients Undergoing Coronary Artery Bypass Grafting Surgery With Cardiopulmonary Bypass

Gerald Proteau; J. Tsoporis; C. Mazer; S. Izhar; D. Latter; Lee Errett; Thomas G. Parker


Canadian Journal of Cardiology | 2012

309 Soluable Receptor For Advanced Glycation End Products In Diabetic And Non-Diabetic Patients With Atrial Fibrillation Undergoing Coronary Artery Bypass Grafting Surgery With Cardiopulmonary Bypass

J. Tsoporis; V. Salpeas; Gerald Proteau; S. Izhar; I.K. Rizos; Thomas G. Parker


Canadian Journal of Cardiology | 2011

290 S100B: Role in cardaic remodeling and function following myocardial infarction in diabetes

F. Mohammadzadeh; Jean-Francois Desjardins; Gerald Proteau; J.N. Tsoporis; Howard Leong-Poi; Thomas G. Parker

Collaboration


Dive into the Gerald Proteau's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Tsoporis

University Health Network

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Duncan J. Stewart

Ottawa Hospital Research Institute

View shared research outputs
Top Co-Authors

Avatar

Lee Errett

St. Michael's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge